

Shai Mulinari

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1808303/shai-mulinari-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

56
papers

671
citations

15
h-index

23
g-index

59
ext. papers

847
ext. citations

3.5
avg, IF

4.89
L-index

#	Paper	IF	Citations
56	Monoamine theories of depression: historical impact on biomedical research. <i>Journal of the History of the Neurosciences</i> , 2012 , 21, 366-92	0.7	53
55	Intersectionality and risk for ischemic heart disease in Sweden: Categorical and anti-categorical approaches. <i>Social Science and Medicine</i> , 2017 , 177, 213-222	5.1	43
54	Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries. <i>International Journal of Health Policy and Management</i> , 2018 , 7, 504-509	2.5	43
53	The tyranny of the averages and the indiscriminate use of risk factors in public health: The case of coronary heart disease. <i>SSM - Population Health</i> , 2017 , 3, 684-698	3.8	40
52	Chronic Obstructive Pulmonary Disease in Sweden: An intersectional multilevel analysis of individual heterogeneity and discriminatory accuracy. <i>SSM - Population Health</i> , 2018 , 4, 334-346	3.8	38
51	DRhoGEF2 and diaphanous regulate contractile force during segmental groove morphogenesis in the Drosophila embryo. <i>Molecular Biology of the Cell</i> , 2008 , 19, 1883-92	3.5	36
50	Contemporary Epidemiology: A Review of Critical Discussions Within the Discipline and A Call for Further Dialogue with Social Theory. <i>Sociology Compass</i> , 2016 , 10, 153-171	1.9	32
49	Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation. <i>PLoS Medicine</i> , 2015 , 12, e1001785	11.6	29
48	Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry's Disclosure UK database, 2015 and 2016 cohorts. <i>BMJ Open</i> , 2018 , 8, e023094	3	27
47	Exposing drug industry funding of UK patient organisations. <i>BMJ, The</i> , 2019 , 365, l1806	5.9	24
46	Expression and regulation of SpEzle-processing enzyme in Drosophila. <i>FEBS Letters</i> , 2006 , 580, 5406-10	3.8	24
45	An intersectional approach to multilevel analysis of individual heterogeneity (MAIH) and discriminatory accuracy. <i>Social Science and Medicine</i> , 2017 , 178, 217-219	5.1	20
44	Analysis of Pharmaceutical Industry Payments to UK Health Care Organizations in 2015. <i>JAMA Network Open</i> , 2019 , 2, e196253	10.4	18
43	Questioning the discriminatory accuracy of broad migrant categories in public health: self-rated health in Sweden. <i>European Journal of Public Health</i> , 2015 , 25, 911-7	2.1	18
42	Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012. <i>PLoS Medicine</i> , 2016 , 13, e1001945	11.6	16
41	Misleading advertising for antidepressants in Sweden: a failure of pharmaceutical industry self-regulation. <i>PLoS ONE</i> , 2013 , 8, e62609	3.7	15
40	Two-Thirds of Survey Respondents in Southern Sweden Used Complementary or Alternative Medicine in 2015. <i>Complementary Medicine Research</i> , 2017 , 24, 302-309	1.3	13

39	Measures of discriminatory accuracy and categorizations in public health: a response to Allan Krasnik's editorial. <i>European Journal of Public Health</i> , 2015 , 25, 910	2.1	13
38	Regulating drug information in Europe: a pyrrhic victory for pharmaceutical industry critics?. <i>Sociology of Health and Illness</i> , 2013 , 35, 761-77	3	13
37	Rho-guanine nucleotide exchange factors during development: Force is nothing without control. <i>Small GTPases</i> , 2010 , 1, 28-43	2.7	13
36	Regulating Pharmaceutical Industry Marketing: Development, Enforcement, and Outcome of Marketing Rules. <i>Sociology Compass</i> , 2016 , 10, 74-86	1.9	11
35	Does Maternal Country of Birth Matter for Understanding Offspring's Birthweight? A Multilevel Analysis of Individual Heterogeneity in Sweden. <i>PLoS ONE</i> , 2015 , 10, e0129362	3.7	11
34	Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK. <i>Health Policy</i> , 2019 , 123, 1244-1250	3.2	10
33	Categorical and anti-categorical approaches to US racial/ethnic groupings: revisiting the National 2009 H1N1 Flu Survey (NHFS). <i>Critical Public Health</i> , 2018 , 28, 177-189	2.6	10
32	Unhealthy marketing of pharmaceutical products: An international public health concern. <i>Journal of Public Health Policy</i> , 2016 , 37, 149-59	2.9	9
31	Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries. <i>Health Policy</i> , 2021 , 125, 915-922	3.2	9
30	Revisiting the pharmaceuticalisation of pandemic influenza using Lukes's framework of power. <i>Sociology of Health and Illness</i> , 2020 , 42, 327-341	3	8
29	Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of sleep product reviews. <i>Health Research Policy and Systems</i> , 2017 , 15, 93	3.7	7
28	Divergence and convergence of commercial and scientific priorities in drug development: The case of Zeldin, the first SSRI antidepressant. <i>Social Science and Medicine</i> , 2015 , 138, 217-24	5.1	6
27	The specificity triad: notions of disease and therapeutic specificity in biomedical reasoning. <i>Philosophy, Ethics, and Humanities in Medicine</i> , 2014 , 9, 14	2.2	6
26	Under-reported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016). <i>BMJ Open</i> , 2020 , 10, e037351	3	6
25	Overuse of methylphenidate: an analysis of Swedish pharmacy dispensing data. <i>Clinical Epidemiology</i> , 2018 , 10, 1657-1665	5.9	6
24	Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs. <i>PLoS ONE</i> , 2020 , 15, e0235021	3.7	4
23	Hedgehog, but not Odd skipped, induces segmental grooves in the <i>Drosophila</i> epidermis. <i>Development (Cambridge)</i> , 2009 , 136, 3875-80	6.6	4
22	Failure of Responsive Regulation? Pharmaceutical Marketing, Corporate Impression Management and Off-Label Promotion of Enzalutamide in Europe 2020 , 2631309X2097047		4

21	Appropriate assessment of ethnic differences in adolescent use of psychotropic medication: multilevel analysis of discriminatory accuracy. <i>Ethnicity and Health</i> , 2016 , 21, 578-95	2.2	4
20	Testosterone prescribing in the population-a short social epidemiological analysis in Sweden. <i>Pharmacoepidemiology and Drug Safety</i> , 2016 , 25, 11-5	2.6	4
19	Sociodemographic patterns in pharmacy dispensing of medications for erectile dysfunction in Sweden. <i>European Journal of Clinical Pharmacology</i> , 2018 , 74, 209-218	2.8	4
18	Pharmaceutical lobbying and pandemic stockpiling of Tamiflu: a qualitative study of arguments and tactics. <i>Journal of Public Health</i> , 2018 , 40, 646-651	3.5	4
17	Genetics and democracy-what is the issue?. <i>Journal of Community Genetics</i> , 2013 , 4, 181-8	2.5	3
16	The whistleblowing drama behind Astellas's suspension from the ABPI. <i>BMJ, The</i> , 2019 , 366, l4353	5.9	2
15	Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review.. <i>BMJ Open</i> , 2021 , 11, e053138	3	2
14	The will of Congress? Permissive regulation and the strategic use of labeling for the anti-influenza drug Relenza. <i>Social Studies of Science</i> , 2020 , 50, 145-169	2.4	2
13	Pharmaceutical lobbying and pandemic stockpiling: A feeling of d... in the Nordic countries and why the sociological perspective is crucial to understand COVID-19. <i>Acta Sociologica</i> , 2020 , 63, 439-442	1.7	2
12	Regulatory scientists's work has important ramifications for public health and should be open to public scrutiny. <i>Health Research Policy and Systems</i> , 2018 , 16, 98	3.7	1
11	Let The Drugs Lead The Way! On the Unfolding of a Research Program in Psychiatry. <i>Philosophy, Psychiatry and Psychology</i> , 2018 , 25, 289-302	0.9	1
10	Is there evidence for the racialization of pharmaceutical regulation? Systematic comparison of new drugs approved over five years in the USA and the EU. <i>Social Science and Medicine</i> , 2021 , 280, 114049	5.1	1
9	Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act. <i>Big Data and Society</i> , 2022 , 9, 205395172110696	5.3	0
8	Conceptual unclarity about COVID-19 ethnic disparities in Sweden: Implications for public health policy.. <i>Health (United Kingdom)</i> , 2022 , 13634593221074866	1.9	0
7	Disclosure of Pharmaceutical Industry Funding of Patient Organisations in Nordic Countries: Can Industry Self-Regulation Deliver on its Transparency Promise?. <i>International Journal of Health Services</i> , 2022 , 207314221083871	2	0
6	Drug company payments to General Practices in England: Cross-sectional and social network analysis. <i>PLoS ONE</i> , 2021 , 16, e0261077	3.7	0
5	The making of a Swedish strategy: How organizational culture shaped the Public Health Agency's pandemic response.. <i>SSM Qualitative Research in Health</i> , 2022 , 100082		0
4	Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs 2020 , 15, e0235021		

- 3 Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs **2020**, 15, e0235021
- 2 Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs **2020**, 15, e0235021
- 1 Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs **2020**, 15, e0235021